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context, and consider alternatives to advance in RD coverage. Methods: A review 
of national and international literature was conducted with two main lines: papers 
available in bibliographic databases (MEDLINE, Cochrane, LILACS, among others), 
and governmental and non-governmental organizations documents, through search 
engines such as Google and Yahoo. Results: Relevant findings were arranged in a 
matrix that compare experiences according to different dimensions. Among them, 
there are two elements in the strategies classifications that must be emphasized: 
policy - or a legal framework for guidelines to address the problem - , and formal 
mechanisms of Health Technology Assessment (HTA) - that define the incorporation 
of new drugs to the health system -. The presence of these aspects, its development, 
and their distinctive features for each country, sets different financial scenarios 
for RD coverage. ConClusions: Chile is in an incipient stage of development in 
financing for DRD. International experience gives useful lessons for the develop-
ment of a funding policy for DRD in Chile. The way of structuring the policy frame-
work, technology assessment, funding and organization of the service offering, has 
an impact on the access of the population to DRD.
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objeCtives: The development of orphan drugs (OD) has substantially increased 
in the last decade. The objective of this study was to describe the trends in OD 
approvals from 2002 to present in the United States. Methods: We selected all 
OD approved between 2002 and 2013 from the FDA Orphan Products database. We 
extracted OD characteristics, especially all drug indications (with drug status as 
orphan/non orphan per therapeutic indication), the prevalence of the rare disease 
and the substance patent date. Frequency of approvals was described over time by 
therapeutic areas, prevalence of disease [rare vs. ultra rare (≤ 20 patients/million)] 
and duration of substance patent. Number of orphan indications by drug was also 
assessed over the last decade. Results: Since 2002, 143 OD were approved with 
162 indications for which the drugs were granted an orphan status (‘orphan indica-
tion’). The number of approved indications has increased by 76% when comparing 
2011-2013 period to 2008-2010 period. Oncology was found to be the major indica-
tion area, accounting for 36% of overall indications, followed by gastroenterology 
(8%) and hematology (7%). Across all indication areas, OD approvals proportion in 
oncology remained relatively stable over time, while other areas appeared randomly 
distributed over the years. About 12% of OD was approved in 2 or more indications, 
with a stable number over time. Half of approved OD displayed less than 7 years 
patent protection, or the period of exclusivity granted by the Orphan Drug Act. Ultra 
OD indications represented 27% of overall approvals, with 41% of ultra orphan indi-
cations approved in the last 3 years. ConClusions: This analysis confirmed the 
increase of OD approvals with a substantial proportion in oncology area between 
2002 and 2013. The 7 years exclusivity is critical for half of the products. No specific 
trends could be captured in the studied period.
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objeCtives: To understand real-world treatment patterns of CLL, the use 
of agents/regimens across all lines of therapy was evaluated in EU5 countries 
during the years 2010-2013. Methods: IPSOS Health care projected rituximab 
use for the treatment of CLL based on patient diaries. Representative panels of 
oncologists (N = 509) completed forms directly from reviews of patients’ charts 
and provided information on how they manage patients in everyday practice. A 
total of 104 physicians provided CLL patient information across first-, second-, 
and third-line CLL treatments. Important data such as age, comorbidities, and 
therapy goals were also abstracted. Results: According to the most recent 
annually projected data, a total of 37,119 patients with CLL are estimated to have 
been treated in the EU5 with any anticancer drug therapy between July 2012 and 
June 2013. The majority of these patients (23.1%) are estimated to have received 
fludarabine-cyclophosphamide-rituximab followed by bendamustine-rituximab 
(17.4%), chlorambucil (16.2%), fludarabine (7.2%), single-agent rituximab (5.8%), 
and chlorambucil-rituximab (5.6%). The data show higher rituximab monotherapy 
share in later lines of therapy for CLL (first-line, 0.3%; second-line, 8.2%, third-line 
or more, 22.1%) irrespective of age. Approved monoclonals (alemtuzumab, 2%, and 
ofatumumab, 4%) are not widely used in relapsed CLL. Our data also indicates 
that single-agent rituximab is now more commonly used in clinical practice than 
chlorambucil (22.1% vs 9.2%, respectively) as third-line treatment and above in 
patients with CLL. Among this subset of patients, diabetes is the most common 
comorbidity (13%). ConClusions: Rituximab is utilized either as a combinational 
or single-agent regimen across all lines of therapy in CLL and more commonly 
used in second-line treatment and above. No standard therapy is available for 
relapsed elderly or more comorbid CLL patients. This data may serve as real-world 
outcomes which can help in designing appropriate or interpreting outcomes of 
clinical trials programs.
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objeCtives: In most developed countries, policies incentivize manufacturers to 
invest in developing orphan drugs (OD) as the return on investment is unlikely. 
The objective of this study was to assess the overall performance of OD policies 
on development and revenue of OD. Methods: We identified on FDA website the 
yearly number of OD approved. We gathered revenue associated to OD from compa-
nies and individual products perspective through IMS sales database, Datamonitor 
reports, and companies’ websites and annual reports. We reviewed published OD 
forecasts. Results: In the US, the number of yearly approved drugs grew from less 
than 5 per year before 2000 to more than 20 in the last 3 years. In 2012, the turnover 
of OD business reached US$ 83 billion. The growth of this part of the pharmaceu-
tical market is very fast with a sales forecasting of US$ 127 billion in 2018 (153% 
compared to 2012). In 2010, 65 products generated more than US $100 million rev-
enue, 39 more than US$500 million, and 24 more than US $1 billion. Seven leading 
companies generate from US$9.9 to 1.7 billion yearly revenue with OD portfolio, 
representing a large proportion of the company turnover. This represents a serious 
burden on health insurance budget in most countries and will obviously continue 
to be subject to serious cost-containment measures. ConClusions: OD incentive 
policies reached their objective by contributing to a large increase of number of OD 
approved. Revenue associated to OD raises the question of appropriateness of OD 
policies as some products are among the top selling products. There is a need to 
review the OD policies and ensure it contribute to enhance development of product 
that would have not reached the market without solid incentive. Some authors 
proposed to revise the prevalence threshold to define OD.
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bACkgRound: Traditional health technology assessment is based on cost-effec-
tiveness, and is the foremost method used by decision-making bodies to inform 
funding decisions. This method is insufficient for expensive rare disease treatment 
decisions as it is premised on efficiency. Other factors guide the decision to fund 
rare disease treatments, including decision-maker values. With Canada’s drug 
costs being borne by the public, it is essential that societal values be understood by 
health ministries, particularly for rare diseases where large resources serve a small 
population. objeCtives: Identify the value-based criteria society feels are most 
important in decision making, the relative weight of these values, and whether 
rarity is strongly valued. Methods: A literature review revealed 13 values other 
than cost which have been used for value-based funding decisions. 2211 Canadians 
were surveyed online and asked to rank the values, and then perform an analytic 
hierarchy process of pairwise comparisons in order to attain both their rank and 
weight. Results: The factors selected in the top 5 for the majority of our subjects 
were: The ability of the drug to improve quality of life (66%) and quantity of life (50%), 
ability of drug to work (61%), severity of disease (60%) and safety (65%).These values 
were weighted 4-5 fold more important than those ranked lowest: unmet need, 
socioeconomic status, rarity, and adherence. Rarity had a relative weight of 0.02, the 
second least important value. Factors related to rare diseases such as severity of dis-
ease (0.12), Equity (0.07) and unmet need (0.04), were ranked higher. ConClusions: 
We have determined the most important factors Canadians feel should be used 
in value-based funding as well as their relative weight. These results have broad 
applications not limited to rare diseases. If rare diseases are to undergo value-based 
funding, our results indicate rarity alone may not be sufficient justification.
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objeCtives: This study aimed to evaluate the cost-utility of home based care versus 
no home based care policy of factor VIII and factor IX concentrate in Thai hemophilia 
A and B patients who had no inhibitor or less than 5 Bethesda units (BU). Methods: 
A Markov Model was used to evaluate the cost-utility of the two policies. The first 
policy was “no home bases care” where patients were treated with blood compo-
nents only when admitted at the hospital but without home treatment. The second 
policy was “home based care” where factors were prescribed and infused for treat-
ment of early bleeding episodes at home. Input parameters related to clinical and 
cost were obtained from primary data collection at the National Health Security 
Office, while patients’ quality of life was surveyed from mailed-questionnaire. Both 
costs and health outcomes were discounted at 3%. One-way and probabilistic sen-
sitivity analysis was performed to assess uncertainty surrounding model param-
eters. Results: Based on governmental perspective, “home based care” policy had 
cost saving in moderate and severe patients when compared with “no home based 
care” policy; while in mild hemophilia patients, the incremental cost-effectiveness 
ratio (ICER) was 80,542 THB or 2,684.73 US$ (30 THB:US$). ConClusions: At the 
ceiling threshold of one time of Gross Domestic Product (GDP) per capita (120,000 
THB per QALY gained), “home based care” policy was cost-effective when compared 
with “no home based care” policy.
PSY61
inTernaTiOnal exPerienCe leSSOnS fOr COverage Of rare diSeaSeS in 
Chile
Quirland C, Lenz R
University of Chile, Santiago, Chile
bACkgRound: In Chile, there is no official definition of Rare Disease (RD) yet. Each 
type of RD affects few people. However, taken together they are a public health 
problem. The subject is on the public agenda in form of a fund for Drugs for Rare 
Diseases (DRD). objeCtives: Review and describe RD financing strategies in major 
international experiences, in order to compare the situation of Chile in the global 
